$ONT

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

Oxford Nanopore Technologies' stock rose 6.6% after its interim results showed improved profitability, with gross margin expanding to 62.2% and adjusted EBITDA losses halving. The company also announced a new licensing deal expected to generate $20 million in fees. Berenberg maintained a Buy rating but lowered its price target to £2.00. The stock is still below its 52-week high of 215.6p.

Onterris (NYSE: ONT) said it won more than $9 million in new project awards in the first half of 2026 from a long-standing global integrated energy client. The awards follow a multi-million-dollar five-year global contract awarded in 2025 for assessment, remediation and reclamation. Onterris cites a 20+ year partnership and expanded services across regions.

Analysts’ views are mixed on industrial stocks VSE (VSEC) and Onterris (ONT). Truist’s Alexandra Mandery kept a Buy on VSE; consensus is Strong Buy with an average $259 target. For Onterris, Evercore ISI’s Durgesh Chopra downgraded to Hold with a $13 target; Barclays also downgraded to Hold at $15.

Bank of America downgraded Onterris, Inc. to Underperform from Neutral and cut its price target to $18 from $31, according to the note cited in the article. The stock is shown trading around $15.24 at the time of publication, with the article referencing Onterris’ recent earnings call.

Onterris (NYSE:ONT) reported Q2 CY2026 revenue of $186.7 million, down 20.4% year on year, missing analysts’ estimates. The company’s full-year revenue guidance midpoint was $765 million, 10.9% below consensus. Non-GAAP EPS was $0.51, above estimates, and the stock fell 17.5% to $18.73 after results.

Onterris, Inc. (ONT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 5, 2026, the Board of Directors (the “Board”) of Onterris, Inc. (the “Company”) declared a dividend of one preferred share purchase right (a “Right”), payable on August 17, 2026, for each share of common stock, par v

Onterris, Inc. (ONT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Onterris Reports Second Quarter Results, Updates Full-Year 2026 Guidance, and Announces Board-led Strategic Review Process Updates Date and Time of Conference Call to Today, Wednesday, August 5, at 5:30 p.m. Eastern Time Second Quarter 2026 Highlights (comparisons to

Onterris (NYSE: ONT) will report earnings Wednesday after market close. The company missed revenue expectations last quarter with $168.5 million revenue, down 5.2% YoY, while EPS beat. For the upcoming quarter, analysts expect revenue to fall 15% YoY. ONT has an average analyst price target of $27 versus a $21.50 share price.

Onterris (NYSE: ONT) said it hired Kurt Beil as Executive Vice President to lead its global Consulting business, overseeing operations and consulting strategy in the US, Canada, and Australia. He reports to COO James Laws. The company cited Beil’s prior leadership roles at GHD and Arcadis and his environment lead role at FARA Recovery.